Evotec and Almirall enter into a multi-target alliance in medical dermatology

20-May-2022 - Evotec SE and Almirall S.A. (ALM) announced a multi-target alliance in Medical Dermatology. The companies aim to discover and develop novel therapeutics for severe skin diseases, including immune-mediated inflammatory conditions such as atopic dermatitis and non-melanoma skin cancer such as basal ...

Almirall appoints Peter Guenter as new CEO

30-Aug-2017 - Following the succession plan initiated more than a year ago, when Eduardo Sanchiz expressed his wish to devote more time to his family and other interests, the Board of Directors has approved the appointment of Mr. Peter Guenter as CEO of Almirall effective October 1st, 2017. Peter Guenter joins ...

Almirall half-year results 2016

Growth in total revenues and net sales driven by dermatology

27-Jul-2016 - Almirall, the global pharmaceutical company based in Barcelona, has announced its results for the first half of 2016. Eduardo Sanchiz, CEO, commented: "We have delivered a solid set of results in first half of 2016, boosted by Dermatology which puts us on track to achieve our yearly guidance. As ...

Almirall closes the acquisition of ThermiGen LLC

Entering the aesthetics market

11-Feb-2016 - Almirall, S.A. announced the completion of the acquisition of 100% of the share capital of ThermiGen LLC, after all closing conditions have been satisfied. In accordance with the terms of the agreement signed in September 2015, the transaction has been fulfilled and Almirall now owns this medical ...

Almirall completes deal with AstraZeneca in respiratory disease

04-Nov-2014 - Almirall announced that, effective November 1st, it has completed the transaction to transfer to AstraZeneca the rights of Almirall’s respiratory franchise after all closing conditions have been satisfied. AstraZeneca will now own the rights for the development and commercialization of Almirall’s ...

Almirall and BioFocus enter research alliance

Three-year integrated drug discovery alliance is for identifying drug development candidates for treating respiratory disease

26-Jan-2012 - Almirall, S.A. announced that it has formed a research alliance with BioFocus, an affiliate from Galapagos NV.The three-year alliance is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall. Under the terms of the collaboration, BioFocus ...

Almirall enters into Integrated Discovery Agreement with Proteros

30-Sep-2011 - Almirall, S.A. and Proteros biostructures GmbH announced they have entered into a research collaboration to identify small molecule inhibitors against a target selected by Almirall in the field of inflammatory diseases.Under the agreement Proteros will apply its protein structure-based drug ...

Basilea receives milestone payment from distribution agreement for Toctino with Almirall

04-Nov-2010 - Basilea Pharmaceutica Ltd. announces that it has received a milestone payment of EUR 5.5 million under its distribution agreement for Toctino® (alitretinoin) with Almirall, S.A. The milestone payment of EUR 5.5 million relates to Italy where Toctino® will become available in the coming weeks and ...

Evotec Signs Ion Channel Hit Identification Agreement with Almirall

28-Sep-2010 - Evotec AG announced that it has entered into a collaboration with Almirall S.A. (BMAD: ALM), to identify small molecule modulators of an ion channel target, selected by Almirall, involved in respiratory diseases. Evotec will apply its in-depth electrophysiology and ion channel pharmacology ...

Evotec Enters into Long-Term Focused Library Agreement with Almirall

Value Exceeding EUR 2.5 m over the Two-Year Contract Period

26-Jul-2005 - Evotec AG and Almirall Prodesfarma S.A., the leading Spanish multinational company, announced that they have entered into a two-year library synthesis agreement. Applying leading skills in high-speed parallel synthesis, medicinal and com-putational chemistry Evotec will design and synthesise ...